c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 26 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
,
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease,
Science,
doi:10.1126/science.abf7945
A large-scale screen to target SARS-CoV-2 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome is initially expressed as two large polyproteins. Its main protease, M pro , is essential to yield functional viral proteins, making it a key drug target. Günther et al. used x-ray crystallography to screen more than 5000 compounds that are either approved drugs or drugs in clinical trials. The screen identified 37 compounds that bind to M pro . High-resolution structures showed that most compounds bind at the active site but also revealed two allosteric sites where binding of a drug causes conformational changes that affect the active site. In cell-based assays, seven compounds had antiviral activity without toxicity. The most potent, calpeptin, binds covalently in the active site, whereas the second most potent, pelitinib, binds at an allosteric site. Science , this issue p. 642
,
Multilayered Prioritization of Graph Attention Autoencoder–Derived Drug Repurposing Candidates for COVID-19,
Pharmaceuticals,
doi:10.3390/ph19101522
Background/Objectives: The COVID-19 pandemic highlighted the critical need for drug repurposing. While computational graph-based approaches show promise, single analytical methods often fail to capture the complex pathological mechanisms needed for clinical translation. We aimed to prioritize COVID-19 repurposing candidates by combining computational prediction with orthogonal lines of evidence. Methods: We developed a Graph Attention Autoencoder (GATE) framework with multilayered evaluation integrating computational prediction, real-world data, and phenome analyses. Network-based embeddings identified candidates through latent-space similarity within biomedical knowledge graphs. Clinical relevance was assessed by disproportionality analysis (DPA) of an adverse event reporting system, and biological plausibility through gene expression and pathway profiling. Results: Our GATE framework identified 16 candidate drug entities, including 12 already used or recognized in the context of COVID-19 or its symptoms, consistent with the model recovering known drug–disease associations. The remaining four had minimal prior COVID-19 associations (cilastatin, megestrol, drotrecogin alfa, and ethacrynic acid). Of these four, the multilayered evaluation prioritized two: DPA showed significant inverse reporting associations for COVID-19-related adverse event terms for cilastatin (reporting odds ratio [ROR]: 0.19, 95% confidence interval [CI]: 0.09–0.43) and megestrol (ROR: 0.63, 95% CI: 0.42–0.94). Pathway profiling indicated that cilastatin shares molecular signatures with drugs investigated in COVID-19 clinical trials and megestrol with compounds reported as COVID-19 therapeutic candidates; gene expression analyses suggest cilastatin may exert antiviral and anti-inflammatory effects through DPEP1 inhibition. Conclusions: By integrating GATE-based prediction, real-world evidence, and phenome-level pathway profiling, this study enabled multidimensional candidate prioritization that single analytical methods do not provide. These findings, including the proposed mechanisms of action, are computational predictions that await experimental confirmation. They nonetheless provide mechanistic working hypotheses that may streamline subsequent preclinical studies. Prioritizing clinically approved drugs with established safety profiles may facilitate subsequent clinical evaluation, although the risks specific to each drug would need to be weighed. The framework offers a generalizable strategy for rapid candidate identification during pandemics and diseases with unmet therapeutic needs.